Patents Issued in January 2, 2018
-
Patent number: 9855266Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.Type: GrantFiled: March 23, 2017Date of Patent: January 2, 2018Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins UniversityInventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
-
Patent number: 9855267Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.Type: GrantFiled: October 26, 2016Date of Patent: January 2, 2018Assignee: CHDI Foundation, Inc.Inventors: Celia Dominguez, Perla Breccia, Christopher A. Luckhurst, Roland W. Bürli, Andrew J. Stott
-
Patent number: 9855268Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.Type: GrantFiled: February 10, 2014Date of Patent: January 2, 2018Assignee: MERCK PATENT GMBHInventors: Dieter Dorsch, Guenter Hoelzemann, Michel Calderini, Ansgar Wegener, Oliver Poeschke
-
Patent number: 9855269Abstract: The invention provides a method of inhibiting angiogenesis in a patient by administering a compound of formula (I): wherein R1 R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: March 9, 2017Date of Patent: January 2, 2018Assignee: Genentech, Inc.Inventors: Huifen Chen, Terry Crawford, Seth F. Harris, Steven R. Magnuson, Chudi Nbdubaku, Lan Wang
-
Patent number: 9855270Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.Type: GrantFiled: March 12, 2015Date of Patent: January 2, 2018Assignee: GENENTECH, INC.Inventors: Jeffrey J. Hager, James D. Joseph, Jing Qian, Nicholas D. Smith, Edna Chow Maneval, Debasish F. Roychowdhury, Lori Friedman, Deepak Sampath
-
Patent number: 9855271Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.Type: GrantFiled: July 30, 2014Date of Patent: January 2, 2018Assignee: Zenith Epigenetics Ltd.Inventors: John Frederick Quinn, Vladimir Khlebnikov
-
Patent number: 9855272Abstract: Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:Type: GrantFiled: August 23, 2016Date of Patent: January 2, 2018Assignee: Samumed, LLCInventors: John Hood, Sunil Kumar Kc, David Mark Wallace
-
Patent number: 9855273Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.Type: GrantFiled: October 7, 2016Date of Patent: January 2, 2018Assignee: Children's Hospital Medical CenterInventors: Daniel Starczynowski, Garrett W. Rhyasen
-
Patent number: 9855274Abstract: Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPAR? and may be useful for treating conditions mediated by the same.Type: GrantFiled: April 18, 2017Date of Patent: January 2, 2018Assignee: vTv Therapeutics LLCInventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
-
Patent number: 9855275Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: GrantFiled: May 17, 2017Date of Patent: January 2, 2018Assignee: Epizyme, Inc.Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
-
Patent number: 9855276Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.Type: GrantFiled: October 22, 2013Date of Patent: January 2, 2018Assignee: The General Hospital CorporationInventor: David R. Elmaleh
-
Patent number: 9855277Abstract: The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.Type: GrantFiled: July 27, 2009Date of Patent: January 2, 2018Assignee: BIAL—PORTELA & CA, S.A.Inventor: Patricio Manuel Viera Araújo Soares Da Silva
-
Patent number: 9855278Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.Type: GrantFiled: May 27, 2016Date of Patent: January 2, 2018Assignee: Supernus Pharmaceuticals, Inc.Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
-
Patent number: 9855279Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.Type: GrantFiled: October 12, 2007Date of Patent: January 2, 2018Assignee: GALERA LABS, LLCInventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
-
Patent number: 9855280Abstract: The present application provides a composition comprising a core formed by gold nanoparticle, a compound of Formula (I): wherein dashed lines in Formula (I) represent (i) with or without an attachment of benzol group, (ii) a delocalized bond where shown within a ring; R1 is hydrogen or a halogen; R2 is a linker selected from C6-20 alkyl or polyethylene glycol; R3 is C1-20 alkyl, C1-20 substituted alkyl, hexadecanyl amido, pyridinyl, benzyl or pyrimidinyl; and a compound of Formula (II): wherein dashed lines, R1, R2 and R3 are defined as in Formula (II), and M is a metal. The composition has an inhibition ability against a cancer.Type: GrantFiled: November 4, 2016Date of Patent: January 2, 2018Assignee: NATIONAL DONG HWA UNIVERSITYInventors: Ivan Jyh Biau Lin, Tina H. T. Hsu, Shiu-Huey Chou
-
Patent number: 9855281Abstract: A composition for enhancing libido of a pharmaceutically effective amount of a libido-enhancing therapeutic of (5S,10R,13S,17S)-13-methyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula I), (3S,5S,10R,13S,17S)-3-hydroxy-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula II), (5S,10S,13S,17S)-17-hydroxy-13-methyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (Formula III), isomers thereof, analogs thereof, or combinations thereof, and a pharmaceutically acceptable carrier. A method of enhancing libido, by administering the composition to an individual in need of an enhanced libido, and enhancing libido in the individual or animal which is male or female. A method of enhancing libido, by administering the composition of the present invention to an individual at an age when libido and sexual desire have naturally decreased, and enhancing libido in the individual.Type: GrantFiled: November 20, 2014Date of Patent: January 2, 2018Assignee: Scott Freeman Consultant, LLCInventor: Scott Freeman
-
Patent number: 9855282Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.Type: GrantFiled: November 15, 2016Date of Patent: January 2, 2018Assignee: Laboratoire HRA-PharmaInventors: Delphine Levy, Erin Gainer
-
Patent number: 9855283Abstract: The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate (HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis.Type: GrantFiled: March 16, 2017Date of Patent: January 2, 2018Assignee: SHAPERON Inc.Inventors: Seung Yong Seong, Youn Hee Kim
-
Patent number: 9855284Abstract: This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.Type: GrantFiled: December 6, 2016Date of Patent: January 2, 2018Assignee: Pop Test Oncology LLCInventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
-
Patent number: 9855285Abstract: The present invention relates to a method of inhibiting the upregulation of the expression of the proinflammatory cytokine interleukin-22 (IL-22) in activated and differentiated human T-cells, said upregulation being induced by administration of a therapeutically effective amount of a phosphodiesterase 4 (PDE4) inhibitor. The method comprises administering, either sequentially to or simultaneously with the administration of the PDE4 inhibitor, a vitamin D receptor agonist in an amount sufficient to inhibit the upregulation of IL-22 expression.Type: GrantFiled: November 28, 2013Date of Patent: January 2, 2018Assignee: LEO PHARMA A/SInventor: Paola Lovato
-
Patent number: 9855286Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof.Type: GrantFiled: May 13, 2013Date of Patent: January 2, 2018Assignee: Gruenenthal GmbHInventors: Stefanie Frosch, Klaus Linz, Klaus Schiene
-
Patent number: 9855287Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.Type: GrantFiled: August 20, 2015Date of Patent: January 2, 2018Assignees: LIFE TECHNOLOGIES CORPORATION, THE JOHNS HOPKINS UNIVERSITYInventors: Brian Agnew, David Graham, Upinder Singh, Scott Grecian
-
Patent number: 9855288Abstract: The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement.Type: GrantFiled: July 9, 2015Date of Patent: January 2, 2018Assignee: MANNATECH, INCORPORATEDInventor: Robert A. Sinnott
-
Patent number: 9855289Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.Type: GrantFiled: August 5, 2016Date of Patent: January 2, 2018Assignee: Metro International Biotech, LLCInventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
-
Patent number: 9855290Abstract: Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.Type: GrantFiled: December 1, 2015Date of Patent: January 2, 2018Assignee: Icahn School of Medicine at Mount SinaiInventors: Lakshmi A. Devi, Raphael Rozenfeld
-
Patent number: 9855291Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: November 3, 2009Date of Patent: January 2, 2018Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Patent number: 9855292Abstract: The current invention discloses novel approaches to help individuals defend against headaches and body pains with orally-delivered cyanocobalamin, methylcobalamin, adenosylcobalamin, and combinations thereof. Original clinical research conducted by the inventor on almost 2,000 humans yielded surprising and unexpected results showing differences in the frequency and severity of pains in the head and the body favoring cyanocobalamin patients over placebo. In one FDA-approved Phase III study on 1,551 patients, 4.4 percent of headaches and body pains were rated as “Severe” in the cyanocobalamin, group versus 11.5 percent in the placebo group. Once inside the body, cyanocobalamin is converted to methylcobalamin and adenosylcobalamin, but not to hydroxocobalamin.Type: GrantFiled: August 7, 2013Date of Patent: January 2, 2018Inventor: Ernest Timothy Armstrong
-
Patent number: 9855293Abstract: Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.Type: GrantFiled: March 14, 2016Date of Patent: January 2, 2018Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITYInventor: Du Woon Kim
-
Patent number: 9855294Abstract: The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day.Type: GrantFiled: June 19, 2015Date of Patent: January 2, 2018Assignee: Gelesis, LLCInventors: Hassan Heshmati, Eyal S. Ron, Alessandro Sannino, Yishai Zohar
-
Patent number: 9855295Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.Type: GrantFiled: October 27, 2015Date of Patent: January 2, 2018Assignee: CLARUS CLS HOLDINGS, LLCInventors: C. Michael Samson, Bo Liang, Joseph A. Capriotti
-
Patent number: 9855296Abstract: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.Type: GrantFiled: November 16, 2016Date of Patent: January 2, 2018Assignee: The McLean Hospital CorporationInventors: Anne M. Cataldo, Bruce M. Cohen
-
Patent number: 9855297Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.Type: GrantFiled: February 17, 2016Date of Patent: January 2, 2018Assignee: CELLECTISInventors: Philippe Duchateau, André Choulika, Laurent Poirot
-
Patent number: 9855298Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.Type: GrantFiled: May 27, 2016Date of Patent: January 2, 2018Assignees: Kite Pharma, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
-
Patent number: 9855299Abstract: Disclosed herein axe methods and compositions for treating retinal degeneration, such as occurs in retinitis pigmentosa and age-related macular degeneration, using descendents of marrow adherent stem cells that have been engineered to express an exogenous Notch intracellular domain.Type: GrantFiled: March 21, 2016Date of Patent: January 2, 2018Assignee: SanBio, Inc.Inventors: Casey C. Case, Toru Kawanishi, Noriyuki Kuno
-
Patent number: 9855300Abstract: The invention relates to a composition and method used for injuries treatment with a surprisingly therapeutic effect. This composition comprises a population of cells derived from human umbilical cord blood which expresses one of the following markers: CD34, CD45, and CD31; a population of CD34+ derived endothelial cells; and a biomimetic gel, preferably fibrin. The method for obtaining the composition comprises the derivation of a population of endothelial cells from CD34+ cells and then a co-culture of a CD34+ cells with CD34+-derived endothelial cells within a biomimetic gel.Type: GrantFiled: November 28, 2011Date of Patent: January 2, 2018Assignee: CRIOESTAMINAL, SAÚDE E TECNOLOGIA, SA.Inventors: Lino Da Silva Ferreira, Dora Cristina Dos Santos Pedroso
-
Patent number: 9855301Abstract: A laminated graft fabricated from human birth tissue material comprising at least two amniotic membranes, or at least two chorionic membranes, or at least one amniotic membrane and at least one chorionic membrane, and at least one morselized placental composition to form a human birth tissue laminate graft. Methods of processing human birth tissue material to form a laminated graft are also provided. Additionally, methods for treating a wound or defect and methods of promoting regeneration of diseased or damaged tissue are provided.Type: GrantFiled: March 10, 2014Date of Patent: January 2, 2018Assignee: BioDLogics LLCInventor: Timothy R. Brahm
-
Patent number: 9855302Abstract: Provided herein are methods of treatment and/or prevention of cancer by manipulation of commensal microflora. In particular, the amount, identity, presence, and/or ratio of microflora (e.g., gut microflora) in a subject is manipulated to facilitate one or more co-treatments.Type: GrantFiled: June 1, 2016Date of Patent: January 2, 2018Assignee: The University of ChicagoInventors: Thomas F. Gajewski, Ayelet Sivan, Leticia Corrales
-
Patent number: 9855303Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.Type: GrantFiled: January 25, 2017Date of Patent: January 2, 2018Assignee: Seres Therapeutics, Inc.Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
-
Patent number: 9855304Abstract: The invention relates to the use of Lactobacillus rhamnosus strain CNCM 1-3690 for reducing body fat accumulation and treating disorders resulting therefrom, such as overweight, obesity, and obesity-related disorders.Type: GrantFiled: November 12, 2012Date of Patent: January 2, 2018Assignees: Compagnie Gervais Danone, Biopolis S.L.Inventors: Gianfranco Grompone, Daniel Ramon Vidal, Patricia Martorell Guerola, Salvador Genoves Martinez, Josefa Ortiz Serrano, Silvia Llopis Pla, Nuria Gonzalez Martinez
-
Patent number: 9855305Abstract: The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.Type: GrantFiled: March 29, 2016Date of Patent: January 2, 2018Assignee: Companion Therapeutics LLCInventors: Julio César Villamil Torres, Camilo Rey Ferro
-
Patent number: 9855306Abstract: A Portulaca oleracea L. extract feed additive and a preparation method thereof are provided. The Portulaca oleracea L. extract feed additive takes a Portulaca oleracea L. extract and a carrier as raw materials. The Portulaca oleracea L. extract is prepared by the ultrasonic auxiliary water extraction. The preparation method of the present invention has less raw material waste, high activity component content in the extract and acquisition rate of the extractum, which facilitates improving the effect efficiency and reducing production cost. The Portulaca oleracea L. extract feed additive as a natural plant feed additive is capable of improving the animal's metabolism, increasing the animal's relative weight gain, improving the animal's survival rate, reducing the disease incidence of various diarrhea symptoms, decreasing the animal's stress response and increasing the animal productivity.Type: GrantFiled: April 15, 2015Date of Patent: January 2, 2018Assignee: Shanghai Zhao Xiang Biological Technology Co., LTDInventors: Jiaming Chen, Xuefeng Chen, Ling Lu, Ting Shu, Zili Chen, Ziqiang Chen, Danrong Zheng, Shunjie Huang
-
Patent number: 9855307Abstract: The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the management of inflammatory mucosal diseases of both viral and non-viral origin.Type: GrantFiled: March 12, 2014Date of Patent: January 2, 2018Assignee: Izun Pharmaceuticals CorporationInventors: William Z. Levine, Aron J. Saffer, Mina Fran
-
Patent number: 9855308Abstract: The present invention provides a nutraceutical composition, a process for the preparation of the nutraceutical composition useful for amelioration of peri- and post-menopausal symptoms in women. The nutraceutical composition is stable, directly compressible, water soluble, free flowing form having particle size not more than 2.0 ?m comprising extract of Trigonella foenum-graecum, at least one bioavailable form of magnesium and vitamin E. The present invention also provides a method of treating ameliorating, treating and/or preventing peri- and post-menopausal discomforts in a subject suffering from peri- or post-menopausal symptoms comprising administering to the subject a therapeutically effective amount of the nutraceutical composition.Type: GrantFiled: September 17, 2015Date of Patent: January 2, 2018Assignee: AKAY FLAVOURS & AROMATICS PVT. LTD.Inventors: Krishnakumar Illathu Madhavamenon, Balu Paulose Maliakel, Shamshad Begum Saddapalli, Jayalakshmi Hosakere Krishnamurthy, Geetha Kalaiah, Vasundhara Mariappa, Suresha Sanaba Venkataiah
-
Patent number: 9855309Abstract: Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.Type: GrantFiled: October 10, 2014Date of Patent: January 2, 2018Assignees: Nutriquine N.V., JAMP Pharma CorporationInventors: Guy Chamberland, Peter Bollen
-
Patent number: 9855310Abstract: The present invention relates to Coix seed oil extracted from Semen Coicis, pharmaceutical preparations thereof, and the use thereof in the treatment of tumors and inflammation. Specifically, the Coix seed oil contains 8 triglyceride ingredients in the following mass percentages: trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76%, and 1-palmitin-2,3-diolein 8.06-11.58%.Type: GrantFiled: June 8, 2015Date of Patent: January 2, 2018Assignee: ZHEJIANG KANGLAITE GROUP CO., LTD.Inventor: Dapeng Li
-
Patent number: 9855311Abstract: Herbal compound formulations using herbs curcuma longa (turmeric), ocimum sanctum (holy basil) and emblica officinalis (amla) in their natural forms and a method of packaging the same for dietary supplement as tablets, wafers, capsules and as teabags where the packaging of individual dosages and the outer packaging may use visual display of color that represents the proportion and presence of different herbs in the herbal compound.Type: GrantFiled: March 25, 2012Date of Patent: January 2, 2018Inventor: Tara Chand Singhal
-
Patent number: 9855312Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.Type: GrantFiled: December 23, 2013Date of Patent: January 2, 2018Assignees: UNIVERSITY OF MIAMI, THE UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Andrew V. Schally, Joshua M. Hare, Norman L. Block, Samirah A. Gomes, Rosemeire M. Kanashiro-Takeuchi
-
Patent number: 9855313Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.Type: GrantFiled: June 23, 2016Date of Patent: January 2, 2018Assignee: MUSC Foundation for Research DevelopmentInventors: Gautam Ghatnekar, Robert Gourdie, Jane Jourdan
-
Patent number: 9855314Abstract: The present invention relates to compositions and methods comprising administering gene modifiers for treating ocular disease.Type: GrantFiled: March 3, 2014Date of Patent: January 2, 2018Assignee: The Schepens Eye Research Insititute, Inc.Inventor: Neena B. Haider
-
Patent number: 9855315Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a heart failure and a method for screening a therapeutic agent for preventing or treating a heart failure. The pharmaceutical composition of the present disclosure comprises the CCN5 or CCN2?CT protein, or a genetic carrier comprising a nucleotide sequence encoding the CCN5 or the CCN2?CT protein, exhibiting dramatic prevention or treatment efficacies on a heart failure even without surgical treatments accompanied with transplanting a donor heart.Type: GrantFiled: March 10, 2011Date of Patent: January 2, 2018Assignee: BETHPHAGEN INC.Inventors: Woo Jin Park, Pyoung Oh Yoon, Dong Kwon Yang